文献速递消化系统肿瘤

转移性结直肠癌的分子亚型与患者对伊立替康为基础治疗的应答相关

Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
PubMed 文献 · Eur J Cancer · 2017-03-08

该研究收集143例有完整临床注释的人结直肠肿瘤样本,用基因表达谱将转移性结直肠癌患者按四种分子分型分为三至六类并分析其与治疗应答及生存的相关性。一种分型与FOLFIRI应答显著相关(P=0.003),其中一个分子亚型占28%的患者对FOLFIRI应答率高达87.5%。该亚型一线接受FOLFIRI相比FOLFOX总生存延长约两倍(40.1个月 vs 18.6个月)。

要点

  • 四种既往在非转移性结直肠癌中定义的分子分型也能正确分类IV期患者。
  • 一种分子分型与FOLFIRI应答显著相关(P=0.003),与FOLFOX(P=0.911)及FOLFIRI+贝伐珠单抗(P=0.190)无关。
  • 占28%的分子亚型对FOLFIRI应答率87.5%,一线FOLFIRI较FOLFOX总生存延长约两倍(40.1个月 vs 18.6个月)。

核心结论

  • 分子分型有助于为转移性结直肠癌患者制定个体化治疗,一线方案对部分患者的总生存有强烈影响。
  • 该结果仍需在大规模前瞻性临床试验中证实。

研究设计与样本

  • 研究收集并分析了143例有完整临床注释(含治疗应答)的人结直肠肿瘤样本。
  • 采用基因表达谱,使用四种不同分子分型将患者分为三至六类。
  • 分析分子亚型与治疗应答、无进展生存和总生存的相关性。

主要发现

  • 四种既往在非转移性患者中定义的结直肠癌分子分型也能正确分类IV期患者。
  • 一种分型与FOLFIRI应答显著相关(P=0.003),与FOLFOX(P=0.911)及FOLFIRI+贝伐珠单抗(P=0.190)无显著相关。
  • 一个分子亚型占患者的28%,对FOLFIRI应答率高达87.5%。
  • 该亚型一线接受FOLFIRI相比FOLFOX总生存延长约两倍(40.1个月 vs 18.6个月)。

关键数值与推荐

  • 一种分子分型与FOLFIRI应答相关P=0.003,与FOLFOX应答相关P=0.911,与FOLFIRI+贝伐珠单抗应答相关P=0.190。
  • 特定分子亚型占28%的患者,对FOLFIRI应答率87.5%。
  • 该亚型一线FOLFIRI总生存40.1个月 vs 一线FOLFOX总生存18.6个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出该结果仍需在大规模前瞻性临床试验中证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab. The aim of this study was to evaluate if recently identified molecular subtypes of colon cancer are associated with response of metastatic patients to first-line therapy. PATIENTS AND METHODS: We collected and analysed 143 samples of human colorectal tumours with complete clinical annotations, including the response to treatment. Gene expression profiling was used to classify patients in three to six classes using four different molecular classifications. Correlations between molecular subtypes, response to treatment, progression-free and overall survival were analysed. RESULTS: We first demonstrated that the four previously described molecular classifications of colorectal cancer defined in non-metastatic patients also correctly classify stage IV patients. One of the classifications is strongly associated with response to FOLFIRI (P=0.003), but not to FOLFOX (P=0.911) and FOLFIRI + Bevacizumab (P=0.190). In particular, we identify a molecular subtype representing 28% of the patients that shows an exceptionally high response rate to FOLFIRI (87.5%). These patients have a two-fold longer overall survival (40.1 months) when treated with FOLFIRI, as first-line regimen, instead of FOLFOX (18.6 months). CONCLUSIONS: Our results demonstrate the interest of molecular classifications to develop tailored therapies for patients with metastatic colorectal cancer and a strong impact of the first-line regimen on the overall survival of some patients. This however remains to be confirmed in a large prospective clinical trial.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Del Rio M, Mollevi C, Bibeau F, et al. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. Eur J Cancer. 2017. PMID: 28284171. doi:10.1016/j.ejca.2017.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。